GLP-1 RAs, also known as GLP-1 analogs or incretin mimetics, simulate GLP-1 effects, and, as such, were originally utilized for the treatment of T2D and obesity (improving glucose homeostasis and modulating the sense of appetite, with low risk of hypoglycemia). The gene discussed is GLP1R; the disease is obesity disorder.